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Abstract
Ghrelin is a recently described acylated peptide, which works as a somatosecretagogue and has described effects on the smooth, skeletal and
cardiac muscle. We examined the production and effects of ghrelin on relaxation of the iris muscles. Contractile effects of 1e5 human ghrelin
(frGhr, 1096 105 M) and 1e5 human des-octanoyl-ghrelin (d-frGhr; 1096 105 M) were tested on iris rabbit sphincter (n ¼ 11 frGhr;
n ¼ 7 d-frGhr), dilator (n ¼ 6 frGhr; n ¼ 6 d-frGhr) and rat sphincter (n ¼ 6 frGhr; n ¼ 8 d-frGhr) precontracted muscles. On rabbit sphincter
the effect of frGhr was also tested in presence of: i) L-NA (105 M; n ¼ 7); ii) indomethacin (105 M; n ¼ 7); iii) DLys3GHRP6 (104 M;
n ¼ 6); and iv) apamin þ carybdotoxin (106 M; n ¼ 6). Furthermore, on rabbit dilator the effect of frGhr was tested in presence of
DLys3GHRP6 (104 M; n ¼ 7). Finally, ghrelin mRNA production was assessed by ‘‘in situ’’ hybridization in Wistar rat eyes (n ¼ 8). In all
muscles, frGhr promoted a concentration-dependent relaxation, maximal at 6 105 M, 1.5e3 min after its addition, decreasing tension by
34.1  12.1%, 25.8  4.8% and 52.1  10.3% in the rabbit sphincter, dilator and rat sphincter, respectively. In the rabbit sphincter the relaxing
effects of frGhr were: (i) enhanced in presence of DLys3GHRP6 (118.1  21.1%); (ii) blunted by indomethacin; and (iii) not altered by apa-
min þ carybdotoxin (36.4  14.4%) or L-NA (52.4  11.4%). Relaxing effects of d-frGhr in rabbit (43.3  5.2%) and rat (77.1  15.3%)
sphincter muscles were similar to those of frGhr. In rabbit dilator muscle, d-frGhr did not significantly alter active tension and the relaxing effect
of frGhr was blunted by GHSR-1a blockage. Ghrelin mRNA was identified in iris posterior epithelium. In conclusion, ghrelin is a novel, locally
produced, relaxing agent of iris dilator and sphincter muscles, an effect that is mediated by GHSR-1a in the former, but not in the latter. Fur-
thermore, in the sphincter it seems to be mediated by prostaglandins, but not by NO or KCa channels.
 2006 Elsevier Ltd. All rights reserved.
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Ghrelin is a recently described acylated peptide, initially
isolated from rat stomach, which works as a somatosecreta-
gogue (Kojima et al., 1999). Growth hormone secretagogues
(GHS) promote GH release by direct action on the pituitary
gland (Smith et al., 1997; Locatelli and Torsello, 1997;
Bowers, 1998; Dieguez and Casanueva, 2000), stimulating
a specific G Protein coupled receptor (GHS type 1a receptor,
1180 A. Rocha-Sousa et al. / Experimental Eye Research 83 (2006) 1179e1187GHSR-1a), which is different from GHRH receptor (Howard
et al., 1996; Muccioli et al., 1998; Smith et al., 1999;
Feighner et al., 1998). Binding sites to the somatosecreta-
gogues have been described in several tissues such as (in or-
der of decreasing binding activity) the myocardium, adrenal
gland, gonads, arteries, lung, liver, skeletal muscle, kidney,
pituitary, thyroid, adipose tissue, veins, uterus, skin and
lymphnode (Papotti et al., 2000; Iglesias et al., 2004). Inter-
estingly, in many of these tissues, the specific binding
values were described as even higher than in the pituitary
gland (Papotti et al., 2000; Bodart et al., 1999; Muccioli
et al., 2000).
Several studies investigated the physiological role of ghre-
lin and GHSR-1a in cardiac, skeletal and smooth muscles. In
cardiac muscle, ghrelin is synthesized and secreted by
cardiomyocytes (Iglesias et al., 2004), and acts as a negative
inotrope. This effect is modulated by cycloxygenase depends
on endocardial endothelium and seems to be independent
from GHSR-1a (Bedendi et al., 2003). In the skeletal muscle,
ghrelin reduces membrane potential, apparently by increasing
chloride’s permeability. This action is directly dependent
of GHSR-1a and is blocked by the specific inhibitor
DLys3GHRP6 (Pierno et al., 2003). In human vascular
smooth muscle, ghrelin appears as the most potent endothe-
lium-independent vasodilator, reversing effectively endothe-
lin-1 (ET-1) mediated constrictions with potency similar to
that of adrenomodullin (Wiley and Davenport, 2002). Ghrelin
also has a potent hypotensive effect associated with reduced
nitric oxide (NO) availability. This effect, in rats, is reversed
by the blockage of the Ca2þ activated Kþ channels (Shinde
et al., 2005).
In the iris sphincter and dilator muscles the relaxing effects
of several substances have been investigated over the last de-
cade. Geyer et al. (1998) showed that b3 adrenergic stimula-
tion elicits a significant relaxation of the bovine iris
sphincter muscle, an effect that was later shown to be potenti-
ated by muscarinic blockage (Barilan et al., 2003). In the same
experimental preparation, it was demonstrated that the endog-
enous NO-guanylyl cyclase-cGMP cascade mediates the non-
adrenergic-non-cholinergic relaxation (Pianka et al., 2000) and
that adrenomodullin relaxes it by increasing intracellular
cAMP (Yousufzai et al., 1999). Finally, both galanin and so-
matostantin inhibit the cholinergic response of the rabbit iris
sphincter muscle, being galanin more potent than somatostantin
in this effect (43% vs 16%) (Yamaji et al., 2003). On the other
hand, pituitary adenylate cyclase activating peptide-27 pro-
motes relaxation of rabbit iris dilator muscles submitted to
electric field stimulation or pre-contracted by phenylephrine
(Yoshitomi et al., 2002).
The effect of some peptides in the iris muscle tone can
modify the aqueous humor drainage mechanisms and induce
changes in the pupil diameter. With the purpose of studying
the effects and physiological relevance of ghrelin in the mod-
ulation of iris smooth muscles relaxation we investigated its
direct effects on the iris sphincter or dilator muscles of rabbit
or rat eyes as well as the presence of its mRNA in the anterior
segment of the rat’s eye.2. Methods
All animal procedures were performed in accordance with
the ARVO statement for the Use of Animals in Ophthalmic
and Vision Research.
2.1. Functional studies
2.1.1. Specimens preparation
The study was performed in isolated iris sphincter (n ¼ 44)
and iris dilator (n ¼ 19) muscles from male New Zealand
white rabbits (Oryctolagus cuniculus; 2.0e3.0 Kg) and in
iris sphincter muscles (n ¼ 14) from Wistar rats. Animals
were euthanized after an injection of pentobarbital sodium
salt (50 mg/kg) into the marginal ear vein (rabbits) or pento-
barbital sodium salt (150 mg/kg) intraperitoneal. The eyes
were immediately enucleated and placed in modified Krebs-
Ringer (KR) solution at 35 C, with the following composition
in mM: NaCl 98; KCl 4.7; MgSO4.7H2O 2.4; KH2PO4 1.2;
glucose 4.5; CaCl2.2H2O 1.8 (2.5 for the rat muscles);
NaHCO3 17; C3H3NaO3 15 and CH3COONa 5. After removal
of the cornea, the iris sphincter or dilator muscles were
quickly excised and immersed in the KR solution. After
dissection, the ends of each piece were tied with silk thread
for mounting in a 15 ml plexi glass organ bath containing
the above-described solutions. One end of the specimen was
connected to an electromagnetic length-tension transducer
(University of Antwerp, Belgium), and the other end was
secured to a clip at the bottom of the organ bath. In rabbits
we tied all the entire strip of the sphincter muscle or a radial
strip of the dilator with 2 mm of width; while in rats we tied
the entire ring. All the surgical procedures were taken under
microscope (Wild M 650, Leica Microsystems, Switzerland).
Solutions were bubbled with 95% O2 and 5% CO2 and pH
was maintained between 7.38e7.42.
Iris muscles were stabilized always at the same preload
(1.1 mN for the rabbit sphincter, 0.5 mN for the rabbit dilator
and 0.2 mN for the rat sphincter) and bathing solutions
replaced every 20 min until muscle length stabilization.
They were then switched to isometric conditions and the
protocols initiated when muscle tension stabilized (usually
after 20 min).
2.1.2. Experimental protocols
2.1.2.1. Rabbit iris sphincter muscles. After stabilization, the
rabbit iris sphincter muscles were contracted, by adding Car-
bachol (107 M) to the organ bath. When a stable contraction
was reached, increasing doses of 1e5 human ghrelin (frGhr;
1096 105 M) were added to the organ bath to generate
concentration-response curves in the absence (n ¼ 7) or pres-
ence of: i) D-Lys3GHRP6 (104 M, n ¼ 6), a GHS receptor 1a
antagonist; ii) Nu-nitro-L-Arginine (LNA: 105 M, n ¼ 7),
a NO-synthase inhibitor; iii) indomethacin (105 M, n ¼ 7),
a cycloxigenase inhibitor; and iv) apamin and carybdotoxin
(106 M þ 106 M, n ¼ 6), inhibitor of the Ca2þ activated
Kþ channels. In a subset of muscles (n ¼ 4) a single dose of
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during 20 min. Finally, the effects of increasing concentrations
of 1e5 human des-octanoyl-ghrelin (d-frGhr; 1096
105 M) were tested in another group of muscles (n ¼ 7).
In these experiments the muscle from the fellow eye was
used as control.
2.1.2.2. Rabbit iris dilator muscles. After stabilization, the
muscles were contracted with epinephrine (104 M). Two con-
tractions, with 30 min duration each, were obtained in the
same muscle. In one of the contractions increasing concentra-
tions of 1e5 human ghrelin (frGhr; 1076 105 M), alone
(n ¼ 6) or in the presence of DLys3GHRP6 (104 M, n ¼ 7),
or 1e5 human des-octanoyl-ghrelin (d-frGhr; 1066
105 M; n ¼ 6) were tested. In the other contraction, which
was used as control, a similar volume of the vehicle was added
to the bath. The order of test and control contractions was
random.
2.1.2.3. Wistar rat iris sphincter muscles. The Wistar rat iris
sphincter muscles were initially pre-contracted by Carbachol
(106 M). Two contractions with duration of 30 min each
were obtained in the same muscle. In one of the contractions
increasing concentrations of 1e5 Human ghrelin (frGhr;
1076 105 M; n ¼ 6) or des-octanoyl-ghrelin (d-frGhr;
1076 105 M; n ¼ 8) were tested, while during the other
contraction, which was used as control, a similar volume of
the vehicle was added to the bath. The order of test and control
contractions was random.
2.1.3. Materials
Human 1e5 ghrelin (frGhr; Gly-Ser-Ser(n-Octanoyl)-
Phe-Leu-NH2) and human 1e5 des-octanoyl-ghrelin (d-frGhr;
Gly-Ser-Ser-Phe-Leu-NH2) were obtained from Peptides In-
ternational (Lousville, Kentucky). This peptide has the same
properties in binding to GHSR-1a as the molecule of Ghrelin
(Bednarek et al., 2000). The other chemicals from Sigma
Chemical Co (St Louis, Mo). Peptides were prepared in
aliquots and stored at 20 C.
2.2. In situ hybridization (n ¼ 8)
After decapitation, Wistar rats (Charles-River, Spain) eyes
were enucleated and fixed immediately. The eye was bisected
equatorially, washed briefly in PBS and fixed in freshly
prepared phosphate-buffered 4% (w/v) neutral buffered paraf-
ormaldeyde during an overnight period. Then the tissues were
consecutively dehydrated in graded ethanol series, cleared in
xylene and embedded in paraffin. Ten-micrometer sections
of the embedded tissue were mounted on SuperFrost Plus
slides (Menzel-Glaser). Some of the sections were stained
with hematoxylin and eosin for light microscope examination.
All handling of tissues and sections was performed under
RNase-free conditions.
Single stranded antisense probe to detect ghrelin was gen-
erated from pGEM-T, containing a 247-bp fragment of ghrelin
cDNA, kindly offered by Dr. Tena-Sampere, SalamancaUniversity. The riboprobe labeled with digoxigenin was pre-
pared by in vitro transcription using a DIG RNA labelling
kit (Roche, Germany), according to manufacturer’s instruc-
tions. The enzymes used for linearization and transcription
were NcoI restriction enzyme and SP6 RNA polimerase,
respectively.
For in situ hybridization, the sections were rehydrated,
washed in PBS. Pretreatment included proteinase K digestion
(2 mg/ml, pH 7.4, at 37 C) followed by postfixation in 4%
paraformaldeyde for 30 min at room temperature and
washing with standard saline citrate (SSC, Promega, USA).
Digoxigenin-labeled ghrelin probe was then added to newly
prepared hybridization solution (50% deionized formamide,
10% dextran sulphate, 1X Denhardt’s reagent, 1 mg/ml of
yeast tRNA, 195 mM NaCl, 8.88 mM TriseHCl, 11 mM
Tris, 5 M EDTA, 4.4 mM Na2HPO4.2H2O, 1 mM Na2HPO4)
at a concentration of 1% (v/v). On each slide 100 ml of
hybridization solution were applied and hybridization was
carried out overnight in a humidified chamber at 70 C. After
hybridization, the slides were washed, and rinsed in maleic
acid buffer (10 mM maleic acid, 15 mM NaCl, 1% Tween
20), pH 7.5, at room temperature. The slides were washed
at 65 C with successive changes of 0.5X SSC, 50% formam-
ide, 0.1% Tween 20 (Sigma, U.K.) and rinsed in maleic acid
buffer (10 mM maleic acid, 15 mM NaCl, 1% Tween 20), pH
7.5, at room temperature. The block reagent (blocking re-
agent 20%, goat serum 20% in maleic acid buffer) and
anti-DIG antibody (Roche, Germany) at 1:2000 dilution
was added to tissue sections and incubated overnight at
room temperature. The development reaction was obtained
by incubating the slides in NTMT buffer (100 mM NaCl,
100 mM TriseHCl, 50 mM MgCl2, 1% Tween 20) with BCIP
(5-bromo-4-chloride-3-indoil-phosphate; Roche, Germany)
and NBT (Nitroblue tetrazolium chloride). This reaction
occurred for 15 h at 37 C.
Negative controls were conducted by the omission of the
anti-sense probe and positive controls by hybridizing the
anti-sense probe with sections from the gastric fundus.
The sections were examined under a light microscope
(Axioskop 2 plus, Carl Zeiss, Germany). Photomicrographs
were taken with an Axiocam color video camera (Carl Zeiss,
Germany).
2.3. Statistical analysis
Data presented as means  SEM. Active tension was
defined as tension developed after muscle contraction minus
resting tension at baseline (Fig. 1). Changes in active tension
were expressed as percent decrease from the value obtained
after stabilization of the contraction elicited by carbachol or
epinephrine. Concentration-response curves of Ghrelin in
each experimental condition were evaluated with one-way
repeated measures ANOVA. Effects of each dose of Ghrelin
in different experimental conditions were tested with one-
way ANOVA. When significant differences were detected
with any of the ANOVA test, the Student-NewmaneKeuls
1182 A. Rocha-Sousa et al. / Experimental Eye Research 83 (2006) 1179e1187Fig. 1. Representative example of iris sphincter muscle active tension during 30 min. Second arrow marks addition of carbachol (107 M), which is followed by an
increase in active tension. The muscle was allowed to stabilize before addition of frGhr (6 105 M, third arrow), which abruptly relaxed the iris muscle (max-
imum effect 1.5e3 min later).test was selected to perform multiple comparisons. P < 0.05
was accepted as significant.
3. Results
3.1. Effects of frGhr on carbachol induced contraction of
rabbit sphincter muscle
Active tension after carbachol-induced contraction of rabbit
iris sphincter muscles was similar in all experimental proto-
cols (3.16  0.09 mN; n ¼ 44).
Effects of a single dose of frGhr (6 105 M) on relaxa-
tion of carbachol-precontracted muscles are illustrated in
a representative example in Fig. 1. After addition of frGhr
active tension quickly fell in the first 1.5e3 min from
3.45  0.47 to 1.27  0.76 mN and then recovered, over the
following 10 min, almost back to the initial tension.
Fig. 2 (upper panel) shows concentration-response curves
obtained 2.5 min after addition of frGhr to the bath.
When compared to control, frGhr induced a significant
decrease of active tension of 10.7  5.6%, 27.2  8.9%
and 34.1  12.1% at 105, 3 105 and 6 105 M
respectively.
3.2. Effects of d-frGhr and blockage of the GHSR-1a
on carbachol-induced contraction of rabbit
sphincter muscle
Fig. 2 (middle panel) shows concentration-response curves
obtained 2.5 min after addition of des-octanoyl-ghrelin
(d-frGhr) to the bath. D-frGhr significantly decreased active
tension by 10.6  3.8%, 20.0  6.1% and 43.3  5.2% at
105, 3 105 and 6 105 M, respectively, when compared
to control. So, d-frGhr also significantly relaxes, in the same
proportion, the iris sphincter muscle as observed with the
addition of frGhr.
With regard to the blockage of the GHSR-1a, D-
Lys3GHRP6 did not alter per se the active tension before the
addition of frGhr. By pretreating the muscles with D-
Lys3GHRP6, we observed a more than threefold bigger relax-
ing effect of frGhr, which decreased active tension by
49.9  12.5, 94.2  19.4 and 118.6  21.1%, respectively at
the concentrations of 105, 3 105 and 6 105 M (Fig. 2
lower panel). So the relaxing effect of frGhr is not mediatedFig. 2. Concentration-response curves of frGhr (upper panel, dotted line) and
d-frGhr (middle panel, dotted line) in carbachol-precontracted iris sphincter
muscles. The lower panel shows a concentration- response curve of frGhr in
presence of D-Lys3GHRP6 (104 M), an inhibitor of the GHRS-1a. In all
panels, active tension decline with time of the iris sphincter muscles of the fel-
low eyes (full lines), which were used as control, are also presented. P < 0.05:
* vs. control.
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3.3. Influence of NOS, COX or the blockage of
Kþ channels on frGhr effects on iris sphincter muscle
Fig. 3 shows concentration-response curves obtained
2.5 min after the addition of frGhr to the bath, either alone
or in presence of L-NA (105 M), indomethacin (105 M) or
Apamin (106 M) þ Carybdotoxin (106 M). These inhibitors
were added to the bath 10 min after the addition of carbachol
Fig. 3. Concentration-response curves of frGhr in carbachol pre-contracted iris
sphincter muscles, in the presence of: i) L-nitro-L-arginine (L-NA; 105 M;
upper panel); ii) indomethacin (105 M; middle panel); and iii) apamin
(106 M) and carybdotoxin (106 M; lower panel). In all panels, active tension
decline with time of the iris sphincter muscles of the fellow eyes (full lines),
which were used as control, are also presented. P < 0.05: * vs. control.and 20 min before the addition of frGhr. None of them altered
per se the active tension prior to frGhr addition.
The relaxing effect of frGhr was blunted by indomethacin.
In these circumstances, active tension only decreased
1.4  6.8, 9.0  6.7 and 20.3  12.1% in response to 105,
3 105 and 6 105 M of frGhr, which failed to reach sta-
tistical significance when compared to control (Fig. 3, middle
panel). On the contrary, in presence of L-NA the relaxing
effect of frGhr was preserved (active tension decreased
29.4  6.2, 37.5  9.4 and 52.4  11.4% at 105, 3 105
and 6 105 M; Fig. 3 e upper panel). Although these values
are as a mean bigger than those obtained with frGhr alone,
such difference failed to reach statistical significance.
Apamin and carybdotoxin (Ca2þ activated Kþ channels
inhibitors) also did not significantly alter the relaxing effect
of frGhr. In these conditions, active tension decreased 12.9 
10.4, 27.1  13.7 and 36.4  14.4% at 105, 3 105 and
6 105 M of frGhr, respectively.
3.4. Effects of frGhr or d-frGhr on epinephrine induced
contraction of rabbit dilator muscle
Active tension after epinephrine-induced contraction of
rabbit iris dilator muscles was similar in all experimental pro-
tocols (1.20  0.05 mN; n ¼ 19).
Fig. 4 shows concentration-response curves obtained
2.5 min after addition of frGhr (upper panel), d-frGhr (middle
panel) and frGhr plus the GHSR-1a inhibitor D-Lys3GHRP6
(lower panel), to the iris dilator muscle precontracted by
epinephrine. The addition of D-Lys3GHRP6 to the muscle
preparation did not alter per se active tension.
When compared to control, only the maximal concentration
of frGhr (6 105 M) significantly decreased active tension
by 25.8  4.8%, while in presence D-Lys3GHRP6 fGhr did
not significantly alter active tension. Also d-frGhr did not sig-
nificantly decrease active tension of the precontracted dilator
muscle, at any of the studied concentrations.
3.5. Effects of frGhr or d-frGhr on carbachol-induced
contraction of rat sphincter muscle
Active tension after carbachol-induced contraction of rat
iris sphincter muscles was similar in all experimental proto-
cols (1.76  0.22 mN; n ¼ 14).
In these protocols frGhr (Fig. 5; upper panel) or d-frGhr
(Fig. 5; lower panel) were added to the bathing solution of
rat iris constrictor muscle precontracted by carbachol. When
compared to control, frGhr decreased active tension by
15.0  7.2%, 36.1  10.4% and 52.1  10.3% at 105,
3 105 and 6 105 M, respectively, while d-frGhr de-
creased it by 29.4  13.1% and 77.1  15.3% at 3 105
and 6 105 M, respectively.
3.6. ‘‘In situ’’ hybridization for ghrelin mRNA in
the anterior segment
Production of ghrelin could be identified in the anterior seg-
ment of rat eyes by ‘‘in situ’’ hybridization for its mRNA.
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(Fig. 6A), as shown by the examination at a higher magnifica-
tion (Fig. 6C), and in some clusters of the iris stroma. Also in
the ciliary epithelium we observed transcripts of Ghrelin’s
mRNA, mainly in the outer face of the ciliary epithelium,
which could be morphologically the non-pigmented ciliary
epithelium (Figs. 6B,D).
4. Discussion
The present study described a novel relaxing effect of ghre-
lin in the iris sphincter and dilator muscles, which is mediated
Fig. 4. Concentration-response curves of frGhr (dotted line, upper panel) or d-
frGhr (dotted line, middle panel) in epinephrine (104 M) pre-contracted rab-
bit iris dilator muscles. The lower panel shows, in similar muscles, a concen-
tration-response curve of frGhr in presence of D-Lys3GHRP6 (104 M; dotted
line). Control curves are presented as full lines. *P < 0.05: vs. control.by prostaglandins. In addition, we provided evidence for the
involvement of different receptor subtypes in the mediation
of this relaxing effect, which seems to be distinct in the
sphincter and dilator, as well as, for the local production of
ghrelin in the anterior segment of the eye.
Addition of frGhr to precontracted iris sphincter muscles
abruptly decreased active muscle tension, which reached its
minimal value 1.5 to 3 min later. This is a profound relaxing
effect with a magnitude similar to the relaxing effect of ghrelin
on ET-1 precontracted smooth muscle from Human internal
mammary artery, considered one of the most potent relaxing
agents in the vasculature (Wiley and Davenport, 2002). How-
ever, in iris sphincter muscle, relaxation elicited by ghrelin
was abrupt with a maximal effect in the first 3 min that almost
disappeared 20 min later, whereas in the arterial smooth mus-
cle the relaxing effect of ghrelin was slow and progressive,
reaching a plateau 10 to 20 min after its addition (Wiley and
Davenport, 2002). This might reflect either a different behav-
ior of vascular and iris smooth muscles, or a distinct response
due to the use of carbachol instead of endothelin-1.
The potent relaxing effect of ghrelin reported in the present
study was observed both in terms of inhibition of the choliner-
gic response in the iris sphincter and of the adrenergic
response in the dilator muscles. Ghrelin therefore adds to
a list of substances whose relaxing effects of the iris sphincter
and dilator muscles have been shown over the last decade
Fig. 5. Concentration-response curves of frGhr (dotted line, upper panel) or d-
frGhr (dotted line, lower panel) in carbachol (106 M) precontracted rat iris
sphincter muscles. Control curves are presented as full lines. P < 0.05: * vs.
control.
1185A. Rocha-Sousa et al. / Experimental Eye Research 83 (2006) 1179e1187Fig. 6. Ghrelin expression pattern in the iris and ciliary body. In situ hybridization revealed a positive signal widely expressed through the iris and ciliary body (A
and B). High levels of ghrelin transcripts were detected in the posterior layer of the iris and some in the iris stroma (panel C arrow), and in the ciliary epithelium
mainly in the non-pigmented cells (panel D; arrow). Scale bar corresponds to 100 mm in panel A and B; 50 mm in panel C and 25 mm in panel D.(Geyer et al., 1998; Yousufzai et al., 1999; Pianka et al., 2000;
Barilan et al., 2003; Hourani et al., 1997; Yamaji et al., 2003).
In the vascular smooth muscle, the hypotensive effect of
ghrelin was recently shown to be mediated by the activation
of the Ca2þ activated Kþ channels and to be potentiated by
the inhibition of NO release (Shinde et al., 2005).
In addition to the smooth muscle, previous studies showed
that ghrelin also decrease contractility of cardiac (Bedendi
et al., 2003; Soares et al., 2006) and skeletal muscles (Pierno
et al., 2003). In the myocardium, PGI2 release from endocar-
dial endothelial cells was proposed to mediate the inotropic
and lusitropic effects of ghrelin (Bedendi et al., 2003; Soares
et al., 2006).
In the present study, the relaxing effect of ghrelin in the iris
sphincter muscle also seems to be dependent of prostaglan-
dins, as inhibition of its production blocked it. Prostaglandin
receptors are widely distributed in various regions of ocular
tissues including iris sphincter muscle, being the EP2 the
most abundant prostaglandin receptor in the ciliary body and
iris (Biswas et al., 2004; Sharif et al., 2004). Interestingly,
EP2 receptors stimulate intracellular cAMP accumulation
and muscle relaxation (Abdel-Latif, 2001), suggesting that
this might be one of the mechanisms underlying ghrelin’s
effects.
Blockage of Ca2þ activated Kþ channels or NO synthesis,
however, did not significantly modify ghrelin’s effect in our
study.
Almost all actions of GHS are believed to be mediated
through a specific seven transmembrane G-protein-coupled
receptor, called GHS receptor type 1a (GHSR-1a), which
was identified in the pituitary and the hypothalamus (Howard
et al., 1996; Muccioli et al., 1998; Pong et al., 1996; McKee
et al., 1997). This receptor is also expressed in thyroid gland,pancreas, spleen, adrenal gland, heart, rat testis, ovary and
prostate cancer cells (Papotti et al., 2000; Iglesias et al.,
2004; Gnanapavan et al., 2002; Tena-Sempere et al., 2002;
Jeffery et al., 2002; Gaytan et al., 2003). In the heart, the neg-
ative inotropic effect of ghrelin has been shown, however, to
be independent of GHSR-1a (Bedendi et al., 2003; Sharif
et al., 2004). Such conclusion was based on the fact that
des-octanoyl-ghrelin, a molecule that does not bind to
GHSR-1a (Hosoda et al., 2000; Bednarek et al., 2000; Kojima
et al., 2001; Torsello et al., 2002; Broglio et al., 2003), has
a negative inotropic effect similar to that of ghrelin (Bedendi
et al., 2003). Also in the fetal development des-octanoyl-
ghrelin has some capacity to bind to a different GHS receptor,
which has an important role in the embryologic process
(Santos et al., 2006). In these conditions the authors presumed
that fetal tissue could express a GHSR different subtype that
binds to des-octanoyl-ghrelin (Nakahara et al., 2006). The
results of the present study also suggest that the relaxing ef-
fects of ghrelin on the iris sphincter muscle are not mediated
by GHSR-1a, as they were also observed in response to
des-octanoyl-ghrelin. Furthermore, in presence of D-Lys3
GHRP6, an inhibitor of that receptor (Veeraragavan et al.,
1992), the relaxing effect of ghrelin was not inhibited, but
rather enhanced more than threefold. It should be, however,
stressed that even if GHSR-1a does not seem to mediate
the relaxing effect of ghrelin, it presumably modulates it,
as inhibition of this receptor enhanced the degree of active
tension decline. On the contrary, in the iris dilator muscle
GHSR-1a seems to mediate the relaxing effect of ghrelin,
as no relaxation was observed in response to des-octanoyl-
ghrelin and the effect of ghrelin was inhibited after the
blockage of the GHSR-1a. So, in the iris muscles the
effect of ghrelin is mediated by more than one receptor,
1186 A. Rocha-Sousa et al. / Experimental Eye Research 83 (2006) 1179e1187the GHSR-1a for the dilator and a different one for the
sphincter muscle.
The relaxing effects of ghrelin, at least in the sphincter iris
muscle, do not seem to be species dependent as similar effects
were observed in the present study in rabbits and rats.
Recent works supports the view that the ciliary body is
a ‘‘neuroendocrine gland’’, which contributes to the aqueous
secretion, regulation of intra-ocular pressure, metabolism of
steroid hormones and production of many biological peptides
(Escribano and Coca-Prados, 2002). Some of these peptides,
synthesized and released by the ciliary epithelium, are neuro-
peptides and hormones usually restricted to endocrine tissues
and cells (Ortego et al., 1996a,b; Ortego and Coca-Prados,
1997, 1999). Production and receptors for neurotensin (Ortego
and Coca-Prados, 1997), galanin (Ortego and Coca-Prados,
1998), natriuretics peptides (Ortega and Coca-Prados, 1999;
Fernandez-Durango et al., 1995), angiotensin II (Cullinane
et al., 2002) and endothelins (Fernandez-Durango et al.,
2003) have been identified in the pigmented and non-
pigmented ciliary epithelium and in cells of the trabecular
meshwork (Escribano and Coca-Prados, 2002). Having shown
that ghrelin’s mRNA is present in the posterior ephitelium of
the iris and in the non-pigmented epithelium of the ciliary
body the present study indicates that ghrelin possibly is also
a product of that ‘‘neuroendocrine gland’’. Ghrelin production
in the posterior epithelium of the iris and its action in the ad-
jacent muscular tissue, suggests that it presumably plays an
important role in the paracrine regulation of muscular kinetics
of the iris. Local concentration of ghrelin is therefore presum-
ably much higher than its circulating levels, indicating that the
relatively higher concentrations at which the maximal relaxing
effects of ghrelin were observed might be physiologically rel-
evant. This effect represents a potential novel mechanism
through which, besides adrenergic, cholinergic and trigeminal
systems, ocular tissues acutely modulate iris tension, pupillary
diameter and therefore trabecular aqueous drainage.
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